Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04175119
Other study ID # 69HCL18_0854
Secondary ID 2019-A01604-53
Status Recruiting
Phase N/A
First received
Last updated
Start date November 25, 2019
Est. completion date October 25, 2027

Study information

Verified date February 2024
Source Hospices Civils de Lyon
Contact Mathilde Bonnefond, PhD
Phone 4 72 13 89 03
Email mathilde.bonnefond@inserm.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The brain is composed of a set of areas specialized in specific computations whose outputs need to be transferred to other specialized areas for cognition to emerge. To account for context-dependent behaviors, the information must be flexibly routed through the fixed anatomy of the brain. The aim of this project is to test a general framework for this flexible communication between brain areas based on nested oscillations. The general idea is that internally-driven slow oscillations (<20Hertz) either set-up or prevent the communication between brain areas. Stimulus-driven gamma oscillations (>30Hertz), nested in the slow oscillations, can then be directed to task-relevant areas of the network. This multimodal, multi-scale approach uses magnetoencephalography using a 3-Dimensional (3D) printed individual head-cast system and transcranial stimulation in experiments manipulating visual processing, attention and memory to test core predictions of this framework. The theoretical approach and the methodological development used in this basic science study will provide the basis for future fundamental and clinical research.


Recruitment information / eligibility

Status Recruiting
Enrollment 160
Est. completion date October 25, 2027
Est. primary completion date October 25, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 36 Years
Eligibility Inclusion Criteria: - 20-36 years old - Right handed - Registered with the French healthcare system - Motivated to participate in the study - Normal or corrected vision - Adequate knowledge of French to be able to follow directions and give informed consent - Capacity to listen and follow study instructions - Use of contraception (in sexually active women) - BMI between 18.5 and 30 - Informed consent for participation in the study Exclusion Criteria: - For All Experiments: - Persons with : - Sleep disorders, neurological or psychiatric illnesses or a history of such problems that could impact quality/variability of data or cooperation and retention of the subject in the study - Migraines or light-sensitive epilepsy - Regular use of medications that impact the central nervous system - Regular use of medications, such as opioids and antidepressants, including Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants - Severe hearing loss - Skin conditions or allergies - Chronic pain, or any other medical conditions conducive to pain sensitivity - A history of stroke or recent trauma to the head - A pacemaker, insulin or other pump, neurostimulator, cochlear implants or other hearing aid, metal stents, prosthesis, or implants, intracerebral clips, implantable defibrillator, cerebral shunt or ventricular catheter, other foreign metal objects in the upper part of the body - Persons unable to adhere to abstinence from the use of drugs or alcohol the day or evening before experimental sessions - Women who are pregnant, breastfeeding, or have given birth in the last 6 months For experiments using magnetoencephalography: - Persons with - claustrophobia - any dental apparatus containing metal including or root canals - any foreign metallic object anywhere in the body - bolts, screws - orthopedic devices or implants - glasses (given the participant cannot use contact lenses) - a head size incompatible with the use of a personalized 3D head-cast or a magnetoencephalograph - Persons having had any surgery prior to the study which puts them at risk for metal objects left in the body For experiments using Magnetic Resonance Imaging (MRI) or Functional Magnetic Resonance Imaging (fMRI) techniques: - Anxious, non-cooperative, or agitated persons - Claustrophobia - Persons having had any surgery prior to the study which puts them at risk for metal objects left in the body For experiments using transcranial stimulation: -Persons with frequent syncope episodes (loss of consciousness) as a result of any particular sensorial stimulations

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Visual attention/perception tasks in healthy participants
The participants complete visual attention and perception tasks while fMRI, EEG, and MEG record brain signals. The tasks acquire responses with a visual saccade or button presses which are coupled to brain responses. These responses are then analyzed to identify patterns of communication between brain areas (within-subject). The flickering stimuli (experiment 1) may alter oscillations in the brain, while participants complete visual attention and perception tasks, leading to a secondary outcome measure distinct from the button presses. The procedure concerning the flickers will be the same for participants. The tACS (experiment 2, 3) delivers input in addition to gathering output while participants complete visual attention and perception tasks. A sinusoidal current at a chosen frequency interacts with the brain's natural oscillations and alters responses. Participants will have sham sessions of tACS as well (there is no group division), The sham will be compared with the stimulation

Locations

Country Name City State
France Centre de Recherche en Neuroscience de Lyon INSERM Bron

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The composite characteristics of the brain oscillations (frequency, synchronization, and interaction between brain oscillations in and between different brain regions and networks) The primary outcome measure is measured using fMRI bold signals (experiment 1), and brain signals obtained through electroencephalography (experiment 1, 3) and magnetoenecephalography (experiment 1, 3), depending on the sessions. The signals are then transformed during analyses and patterns in the composite characteristics are identified. up to 17 months
Secondary The coupling of behavioral responses to stimuli with physiological responses in the brain. Throughout the sessions of neuroimaging. There are 5, 1 or 2, and 1 sessions of neuroimaging for experiment 1, 2, and 3 respectively. The 5 sessions of experiment 1 are over a period of 1 to 17 months. Each session lasts approximately 3 hours including setup.The sessions take place at between 7 and 198 days after inclusion. The time between the sessions is variable. up to 17 months
Secondary Coupling of brain oscillation characteristics in responses to the "flickering" effect There are 5 sessions of neuroimaging for experiment 1. The 5 sessions of experiment 1 are over a period of 1 to 17 months. Each session lasts approximately hours including setup. This outcome measure will be recorded during these 5 interspaced sessions, at between 7 and 198 days after inclusion. The time between the sessions is variable. up to 17 months
See also
  Status Clinical Trial Phase
Completed NCT06326723 - Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects Phase 1
Recruiting NCT00001367 - Diagnosis and History Study of Patients With Different Neurological Conditions
Completed NCT02699710 - Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects Phase 1
Completed NCT02231892 - Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study N/A
Not yet recruiting NCT06441916 - Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions Phase 1
Completed NCT03771586 - A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects Phase 1
Not yet recruiting NCT06337422 - Bioequivalence Study of Generic Celecoxib 200 mg Capsules Phase 1
Completed NCT03302182 - Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects Phase 1
Completed NCT05049343 - Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants Phase 1
Recruiting NCT01629108 - Normal Values in Hearing and Balance Testing
Completed NCT02947854 - Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant Phase 1
Completed NCT02534870 - Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects Phase 1
Completed NCT02224053 - Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers Phase 1
Completed NCT01697436 - A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets Phase 1
Completed NCT01711762 - A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers Phase 1
Completed NCT01684891 - A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers Phase 1
Completed NCT01676584 - A Study of Single Dose RO6811135 in Healthy Volunteers Phase 1
Completed NCT01433575 - A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers Phase 1
Completed NCT01461967 - A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers Phase 1
Completed NCT01414881 - Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects Phase 1